EUCTR2018-001989-42-PL
Active, not recruiting
Phase 1
Multicenter, open label trial to investigate the efficacy and safety of a single oral dose of 1.0 mg/kg macimorelin acetate as growth hormone stimulation test (GHST) in pediatric patients with suspected growth hormone deficiency (GHD) - the DETECT Trial - the DETECT Trial
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Diagnosis of growth hormone deficiency in pediatric subjects
- Sponsor
- Aeterna Zentaris GmbH
- Enrollment
- 100
- Status
- Active, not recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects are eligible to be included in the trial only if all of the following criteria apply:
- •1\. Informed consent of subject, parent(s) or legally acceptable representative (LAR) of subject and child assent, if appropriate, must be obtained before any trial\-related activities. Trial\-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.
- •2\. Male and female pediatric subjects from 2 to less than 18 years of age at the time of signing informed consent.
- •3\. Indication for the performance of growth hormone stimulation test.
- •4\. Presence of a height measurement minimum 6 and maximum 18 months prior to screening.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 100
- •F.1\.2 Adults (18\-64 years) no
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) no
Exclusion Criteria
- •Subjects are excluded from the trial if any of the following criteria apply:
- •Lack of suitability for the trial:
- •1\. Established diagnosis of a disease that is sufficient to explain growth deficiency or metabolic disorders that are also associated with short stature (e.g., Turner syndrome, skeletal dysplasia’s, celiac disease, etc.).
- •2\. Ongoing growth hormone therapy.
- •3\. Presence of hypothyroidism and/or adrenal insufficiency without adequate and stable replacement therapy treatment for at least 30 days prior to first GHST.
- •4\. Treatment with drugs directly affecting the pituitary secretion of somatotropin (e.g., somatostatin analogues, clonidine, levodopa and dopamine agonists) or provoking the release of somatostatin (antimuscarinic agents e.g., atropine).
- •5\. Medical history of ongoing clinically symptomatic psychiatric disorders.
- •6\. 2nd or 3rd degree atrioventricular\-block, prolongation of the QRS complex over 120 milliseconds, prolongation of the QTc interval over 450 milliseconds, or any other clinically significant abnormal electrocardiogram results at the screening ECG as judged by the investigator.
- •7\. Previous participation in this trial. Participation is defined as signed informed consent.
- •8\. Participation in any clinical trial of an approved or non\-approved investigational medicinal product within 30 days before screening.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A research study of how well macimorelin works to find out if children have a lack of growth hormone and how safe it isDiagnosis of growth hormone deficiency in pediatric subjectsTherapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]EUCTR2018-001989-42-SIAeterna Zentaris GmbH100
Active, not recruiting
Phase 1
A research study of how well macimorelin works to find out if children have a lack of growth hormone and how safe it isDiagnosis of growth hormone deficiency in pediatric subjectsTherapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]EUCTR2018-001989-42-DEAeterna Zentaris GmbH100
Active, not recruiting
Phase 1
A research study of how well macimorelin works to find out if children have a lack of growth hormone and how safe it isEUCTR2018-001989-42-ITAETERNA ZENTARIS GMBH100
Active, not recruiting
Phase 1
A research study of how well macimorelin works to find out if children have a lack of growth hormone and how safe it isDiagnosis of growth hormone deficiency in pediatric subjectsMedDRA version: 21.0Level: LLTClassification code 10073227Term: Growth hormone stimulation testSystem Organ Class: 10022891 - InvestigationsTherapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]EUCTR2018-001989-42-SKAeterna Zentaris GmbH100
Active, not recruiting
Not Applicable
Multicenter, open-label study to investigate the efficacy and safety of Cavinton Forte (vinpocetine) tablet in patients with mild cognitive impairment (MCI).Mild cognitive impairmentMedDRA version: 9.1Level: LLTClassification code 10009846EUCTR2006-005841-13-HUGedeon Richter Plc